Apyx Medical Management
Management Kriterienprüfungen 3/4
Apyx Medical CEO ist Charlie Goodwin , ernannt in Dec 2017, hat eine Amtszeit von 8.5 Jahren. Die jährliche Gesamtvergütung beträgt $1.23M , bestehend aus 40.7% Gehalt und 59.3% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.21% der Aktien des Unternehmens, im Wert von $369.90K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.5 Jahre bzw. 6.9 Jahre.
Wichtige Informationen
Charlie Goodwin
Geschäftsführender
US$1.2m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 40.67% |
| Amtszeit als Geschäftsführer | 8.5yrs |
| Eigentum des Geschäftsführers | 0.2% |
| Durchschnittliche Amtszeit des Managements | 2.5yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 6.9yrs |
Jüngste Management Updates
Recent updates
Narrativ-Update • Jun 13
APYX: Expanded Body Contouring Platform Will Drive Future Upside Potential
Analysts have adjusted their price target on Apyx Medical to $6.50 from $6.50, reflecting updated assumptions around the discount rate, profit margin and future P/E, while keeping fair value and revenue growth expectations unchanged. What's in the News Apyx Medical received expanded 510(k) clearance from the U.S. Food and Drug Administration for the AYON Body Contouring System to include power liposuction, allowing multiple body contouring modalities within one platform.Narrativ-Update • May 30
APYX: GLP 1 Skin Tightening Demand Will Drive Future Upside
Apyx Medical's analyst price target has shifted to $6.50 from $6.40, as analysts point to a higher Street target around $6; recent research highlighting stronger guidance into 2026; potential upside from liposuction handpiece approval; and growing international and GLP-1 related demand, alongside updated assumptions for slightly faster revenue growth, a lower discount rate, modestly lower profit margins, and a reduced future P/E multiple. Analyst Commentary Recent Street research highlights a mix of optimism and caution around Apyx Medical, with attention on execution against 2026 guidance, new products, and international expansion.Analyseartikel • May 11
Earnings Update: Here's Why Analysts Just Lifted Their Apyx Medical Corporation (NASDAQ:APYX) Price Target To US$6.50
Apyx Medical Corporation ( NASDAQ:APYX ) investors will be delighted, with the company turning in some strong numbers...Narrativ-Update • May 05
APYX: GLP 1 Skin Tightening And New Tools Will Drive Upside
Analysts have raised their Apyx Medical price target to $6 from $5, citing a stronger recent quarter, higher 2026 guidance and added potential from new product approvals, geographic expansion and growing demand linked to GLP-1 usage. Analyst Commentary Bullish Takeaways Bullish analysts point to the recent quarter, where sales were in line and earnings were ahead of expectations, as support for a higher valuation framework.Narrativ-Update • Apr 21
APYX: GLP-1 Skin Tightening Demand Will Support Future Upside
Analysts have lifted their price targets on Apyx Medical to $6, up from $5, citing a strong quarter; 2026 guidance above prior Street expectations; early traction from the Ayon launch; and potential upside from new product approvals, GLP-1 related skin tightening demand, and international expansion. Analyst Commentary Bullish Takeaways Bullish analysts see the new $6 price target as reflecting stronger confidence in execution after a quarter where sales were in line and earnings were ahead of prior expectations, which they view as supportive for valuation.Narrativ-Update • Apr 05
APYX: GLP-1 Skin Tightening Trend Will Drive Future Upside
Narrative Update on Apyx Medical The updated analyst price target for Apyx Medical moves to $6, with analysts pointing to a strong quarter, 2026 guidance that is ahead of Street expectations, early traction from the Ayon launch, growing skin tightening demand linked to GLP-1 usage, and expansion opportunities outside the U.S. as key supports for the change. Analyst Commentary Recent Street research on Apyx Medical centers on a higher $6 price target and an upgrade to a more constructive stance, driven by operational updates, new product traction, and exposure to GLP-1 related demand trends.Narrativ-Update • Mar 22
APYX: GLP-1 Procedure Demand And International Expansion Will Drive Future Upside
Narrative Update: Apyx Medical Apyx Medical's updated fair value estimate edges up from $6.00 to $6.40 as analysts point to a higher Street price target of $6.00, recent earnings outperformance, 2026 guidance that sits above prior expectations, and additional growth opportunities tied to new product approvals, GLP-1 related demand, and international expansion. Analyst Commentary Recent Street commentary on Apyx Medical is broadly constructive, with analysts pointing to a combination of product momentum, new procedure use cases, and international expansion as key inputs to their updated valuation work.Narrativ-Update • Mar 06
APYX: Strong Revenue Outlook Will Support Future Single Platform Adoption
Analysts have raised their Apyx Medical price target to $6.00, up from $6.00, citing updated assumptions around revenue growth, profit margins, the discount rate and future P/E that together refine their view of the stock's risk and earnings potential. What's in the News Apyx Medical issued preliminary revenue guidance for fourth quarter 2025, with management expecting revenue between $19.0 million and $19.2 million, which the company states represents a 34% year over year increase (Key Developments).Narrativ-Update • Feb 19
APYX: Single Console Platform Will Drive Future Adoption And Margin Expansion
Analysts have modestly adjusted their price target framework for Apyx Medical, reflecting updated assumptions around profit margin and future P/E that contribute to a refined view of fair value at $6.00 per share. What's in the News Apyx Medical issued preliminary revenue guidance for the fourth quarter of 2025, with expected revenue between $19.0m and $19.2m, described by the company as approximately 34% year over year growth (company guidance).Narrativ-Update • Feb 03
APYX: Single Console Platform Will Drive Wider Adoption And Margin Expansion
Narrative Update on Apyx Medical Analysts have raised their price target on Apyx Medical to US$8, reflecting increased confidence that the AYON all in one console, which integrates Renuvion with additional surgical offerings, can attract physicians through its differentiated technology, workflow benefits, and broad patient appeal. Analyst Commentary Recent research updates are framing Apyx Medical as a company where expectations are increasingly tied to execution on the AYON platform and its potential impact on growth, margins, and valuation.Analyseartikel • Feb 03
Subdued Growth No Barrier To Apyx Medical Corporation (NASDAQ:APYX) With Shares Advancing 26%
Despite an already strong run, Apyx Medical Corporation ( NASDAQ:APYX ) shares have been powering on, with a gain of...Narrativ-Update • Jan 20
APYX: Single Console Platform Will Support Future Procedure And Workflow Adoption
Analysts have raised their price target on Apyx Medical to $8, pointing to the AYON system's integrated console design, use of the legacy Renuvion technology, and its appeal to physicians as key supports for the updated view. Analyst Commentary Recent analyst commentary around Apyx Medical has focused on how the AYON system could influence the company’s growth path, execution risks, and valuation framework.Analyseartikel • Jan 13
Is Apyx Medical Corporation (NASDAQ:APYX) Trading At A 45% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Apyx Medical fair value estimate is US$7.24 Apyx Medical is...Narrativ-Update • Jan 06
APYX: Single Console Platform Will Drive Future Procedure Adoption Upswing
Analysts have nudged their fair value target for Apyx Medical to $6.00 per share, citing greater confidence in the AYON system's all in one console design and its potential appeal to physicians and a broadening patient base. Analyst Commentary Bullish Takeaways Bullish analysts point to the AYON system's all in one, single console design as a core driver for their higher fair value targets, arguing that a unified platform can support more efficient procedure volumes and revenue per installed unit over time.Narrativ-Update • Dec 22
APYX: New Surgical Console Rollout Will Drive Stronger Demand Inflection
Analysts have modestly raised their price target on Apyx Medical to $8.00, citing increasing confidence that the AYON system can drive faster adoption and enhance the company’s long term growth and profitability profile. Analyst Commentary Analyst feedback on Apyx Medical has been largely constructive, with the AYON system viewed as a key catalyst for accelerating revenue growth and improving the company’s valuation profile.Narrativ-Update • Dec 08
APYX: Workflow Console Rollout Will Drive Bullish Demand Inflection
Analysts have raised their price target on Apyx Medical to $8.00, citing increasing optimism that the AYON all in one console, which integrates the company's Renuvion technology with multiple surgical offerings, can drive an inflection in demand by streamlining workflows and addressing a large, growing patient base. Analyst Commentary Recent research notes highlight a shift in sentiment as bullish analysts point to AYON as a key driver of Apyx Medical's next phase of growth, underpinning the higher price target.Narrativ-Update • Nov 24
APYX: Recent Product Launch and Equity Raise Will Drive Share Momentum
Analysts have raised their price target for Apyx Medical from $4.50 to $6.00 per share, citing increased growth prospects supported by the successful launch and strong physician appeal of the AYON system. Analyst Commentary Recent analyst feedback reflects a growing optimism around Apyx Medical's outlook, particularly in light of the momentum generated by the AYON system launch and its integration of legacy technology and new surgical offerings.Analyseartikel • Nov 18
Apyx Medical Corporation's (NASDAQ:APYX) Shares Leap 38% Yet They're Still Not Telling The Full Story
Despite an already strong run, Apyx Medical Corporation ( NASDAQ:APYX ) shares have been powering on, with a gain of...Analyseartikel • Nov 07
Is Now The Time To Look At Buying Apyx Medical Corporation (NASDAQ:APYX)?
Apyx Medical Corporation ( NASDAQ:APYX ), is not the largest company out there, but it received a lot of attention from...Narrativ-Update • Nov 07
APYX: Earnings Guidance Increase Will Drive Market Expansion Opportunities
Narrative Update on Apyx Medical: Analyst Price Target Revision Analysts have raised their price target for Apyx Medical from $4.00 to $4.50 per share. This change is attributed to improved profitability and a lower discount rate, even though there is a reduction in projected revenue growth.Analyseartikel • Oct 04
Even With A 26% Surge, Cautious Investors Are Not Rewarding Apyx Medical Corporation's (NASDAQ:APYX) Performance Completely
Apyx Medical Corporation ( NASDAQ:APYX ) shareholders would be excited to see that the share price has had a great...Analyseartikel • Sep 19
Is Apyx Medical (NASDAQ:APYX) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Jul 26
A Piece Of The Puzzle Missing From Apyx Medical Corporation's (NASDAQ:APYX) 34% Share Price Climb
Despite an already strong run, Apyx Medical Corporation ( NASDAQ:APYX ) shares have been powering on, with a gain of...Analyseartikel • Apr 23
The Market Doesn't Like What It Sees From Apyx Medical Corporation's (NASDAQ:APYX) Revenues Yet As Shares Tumble 25%
To the annoyance of some shareholders, Apyx Medical Corporation ( NASDAQ:APYX ) shares are down a considerable 25% in...
Neues Narrativ • Apr 11
AYON Launch And Restructuring Will Create Lasting Opportunities
The launch of the AYON Body Contouring System may significantly drive revenue growth through market expansion and increased equipment sales.Analyseartikel • Mar 05
Apyx Medical Corporation's (NASDAQ:APYX) Shares Lagging The Industry But So Is The Business
With a price-to-sales (or "P/S") ratio of 0.9x Apyx Medical Corporation ( NASDAQ:APYX ) may be sending very bullish...Analyseartikel • Dec 19
Is Now The Time To Look At Buying Apyx Medical Corporation (NASDAQ:APYX)?
While Apyx Medical Corporation ( NASDAQ:APYX ) might not have the largest market cap around , it led the NASDAQGS...Analyseartikel • Nov 23
Apyx Medical Corporation (NASDAQ:APYX) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Apyx Medical Corporation ( NASDAQ:APYX ) shareholders would be excited to see that the share price has had a great...Analyseartikel • Sep 14
Is There An Opportunity With Apyx Medical Corporation's (NASDAQ:APYX) 41% Undervaluation?
Key Insights The projected fair value for Apyx Medical is US$1.98 based on 2 Stage Free Cash Flow to Equity Apyx...Analyseartikel • Aug 07
Apyx Medical Corporation (NASDAQ:APYX) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Apyx Medical Corporation ( NASDAQ:APYX ) shareholders that were waiting for something to happen have been dealt a blow...Analyseartikel • Aug 01
We Discuss Why Apyx Medical Corporation's (NASDAQ:APYX) CEO Compensation May Be Closely Reviewed
Key Insights Apyx Medical will host its Annual General Meeting on 8th of August Salary of US$482.5k is part of CEO...Analyseartikel • Jun 19
Is Apyx Medical (NASDAQ:APYX) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Apr 18
Revenues Working Against Apyx Medical Corporation's (NASDAQ:APYX) Share Price Following 25% Dive
Unfortunately for some shareholders, the Apyx Medical Corporation ( NASDAQ:APYX ) share price has dived 25% in the last...Analyseartikel • Mar 26
Apyx Medical Corporation (NASDAQ:APYX) Analysts Just Slashed This Year's Estimates
Market forces rained on the parade of Apyx Medical Corporation ( NASDAQ:APYX ) shareholders today, when the analysts...Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$9m |
| Dec 31 2025 | US$1m | US$502k | -US$11m |
| Sep 30 2025 | n/a | n/a | -US$15m |
| Jun 30 2025 | n/a | n/a | -US$17m |
| Mar 31 2025 | n/a | n/a | -US$20m |
| Dec 31 2024 | US$976k | US$502k | -US$23m |
| Sep 30 2024 | n/a | n/a | -US$28m |
| Jun 30 2024 | n/a | n/a | -US$28m |
| Mar 31 2024 | n/a | n/a | -US$23m |
| Dec 31 2023 | US$1m | US$483k | -US$19m |
| Sep 30 2023 | n/a | n/a | -US$15m |
| Jun 30 2023 | n/a | n/a | -US$16m |
| Mar 31 2023 | n/a | n/a | -US$21m |
| Dec 31 2022 | US$2m | US$483k | -US$23m |
| Sep 30 2022 | n/a | n/a | -US$19m |
| Jun 30 2022 | n/a | n/a | -US$18m |
| Mar 31 2022 | n/a | n/a | -US$16m |
| Dec 31 2021 | US$2m | US$450k | -US$15m |
| Sep 30 2021 | n/a | n/a | -US$15m |
| Jun 30 2021 | n/a | n/a | -US$14m |
| Mar 31 2021 | n/a | n/a | -US$15m |
| Dec 31 2020 | US$2m | US$450k | -US$12m |
| Sep 30 2020 | n/a | n/a | -US$16m |
| Jun 30 2020 | n/a | n/a | -US$16m |
| Mar 31 2020 | n/a | n/a | -US$16m |
| Dec 31 2019 | US$2m | US$450k | -US$20m |
Vergütung im Vergleich zum Markt: CharlieDie Gesamtvergütung ($USD1.23M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD1.63M).
Entschädigung vs. Einkommen: CharlieDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.
Geschäftsführer
Charlie Goodwin (59 yo)
8.5yrs
Amtszeit
US$1,233,863
Vergütung
Mr. Charles D. Goodwin II, also known as Charlie, has been Chief Executive Officer and Director of Apyx Medical Corporation (formerly known as Bovie Medical Corporation) since December 15, 2017 and serves...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| President | 8.5yrs | US$1.23m | 0.21% $ 369.9k | |
| CFO, Treasurer & Secretary | 2.5yrs | US$851.82k | 0.020% $ 34.9k | |
| Chief Operating Officer | 1.6yrs | US$538.55k | 0.039% $ 67.7k | |
| Senior Vice President | 14.4yrs | US$534.26k | 1.18% $ 2.0m | |
| Chief of Confidence | 1.1yrs | keine Daten | keine Daten |
2.5yrs
Durchschnittliche Betriebszugehörigkeit
58yo
Durchschnittliches Alter
Erfahrenes Management: APYXDas Führungsteam des Unternehmens gilt als erfahren (2.5 Jahre durchschnittliche Betriebszugehörigkeit).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| President | 8.5yrs | US$1.23m | 0.21% $ 369.9k | |
| Lead Independent Director | 15.3yrs | US$164.83k | 0.10% $ 176.3k | |
| Member of Medical Advisory Board | 6.9yrs | keine Daten | keine Daten | |
| Member of Scientific Advisory Board | no data | US$9.30k | keine Daten | |
| Member of Scientific Advisory Board | no data | keine Daten | keine Daten | |
| Independent Director | 6.8yrs | US$145.25k | 0% $ 0 | |
| Independent Non-Executive Chairman | 2.1yrs | US$205.96k | 4.17% $ 7.2m | |
| Member of Medical Advisory Board | 9.4yrs | keine Daten | keine Daten | |
| Member of Medical Advisory Board | 8.1yrs | keine Daten | keine Daten | |
| Member of Medical Advisory Board | 6.9yrs | keine Daten | keine Daten | |
| Member of Medical Advisory Board | 6.9yrs | keine Daten | keine Daten | |
| Independent Director | 4.8yrs | US$141.10k | 0% $ 0 |
6.9yrs
Durchschnittliche Betriebszugehörigkeit
70yo
Durchschnittliches Alter
Erfahrener Vorstand: APYXDie Vorstandsmitglieder gelten als erfahren (6.9 Jahre durchschnittliche Amtszeit).
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/20 08:41 |
| Aktienkurs zum Tagesende | 2026/06/18 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Apyx Medical Corporation wird von 7 Analysten beobachtet. 4 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Michael Gorman | BTIG |
| Sam Eiber | BTIG |
| David Turkaly | Citizens JMP Securities, LLC |